Predictive Factors and Prognostic Relevance of Sunitinib-induced Subclinical and Overt Hypothyroidism in Korean Patients with Metastatic Renal Cell Carcinoma
Minoh Ko1, Hyun Jee Kim1,2, In-Wha Kim1, Tae Min Kim3,4, and Jung Mi Oh1*
1College of Pharmacy, Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, Seoul National University, Seoul 08826, Republic of Korea
2Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Republic of Korea
3Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea
4Cancer Research Institute, Seoul National University, Seoul 03080, Republic of Korea
2Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Republic of Korea
3Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea
4Cancer Research Institute, Seoul National University, Seoul 03080, Republic of Korea
Correspondence to: Jung Mi Oh, College of Pharmacy, Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea
Tel: +82-2-740-8551, Fax: +82-2-882-9560, E-mail: jmoh@snu.ac.kr
Tel: +82-2-740-8551, Fax: +82-2-882-9560, E-mail: jmoh@snu.ac.kr
Received July 28, 2024; Revised September 14, 2024; Accepted September 23, 2024.
This is an Open Access journal distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Abstract
- Background: Sunitinib, commonly used for metastatic renal cell carcinoma (mRCC), often induces hypothyroidism, affecting 27 to 85% of patients. There are clues suggesting an association between sunitinib-induced hypothyroidism and improved survival outcomes. This study aims to identify the predictive factors of sunitinib-induced hypothyroidism and evaluate whether the occurrence of overt or subclinical hypothyroidism predicts tumor outcome in patients with mRCC. Methods: Patients administered to sunitinib for mRCC was included in this retrospective study. Log-rank test and Cox proportional hazards model were conducted to identify predictive factors of hypothyroidism and prognostic factors of progression-free survival (PFS) and overall survival (OS). Results: A total of 156 patients with mRCC treated with sunitinib were included. Predictive factors of sunitinib-induced hypothyroidism were female (odds ratio (OR), 2.77), sunitinib-induced hypertension (OR, 2.99) and dose reduction of sunitinib due to intolerance (OR, 3.57). Sunitinib-induced overt hypothyroidism was a significant prognostic factor in predicting PFS and OS (hazard ratio, 0.38 and 0.23, respectively). Thyroid hormone replacement did not have an influence on PFS and OS. Conclusions: Female patients, patients who experienced sunitinib-induced hypertension and sunitinib dose reduction are at higher risk of hypothyroidism and need close monitoring. Overt hypothyroidism is a strong prognostic factor of sunitinib treatment outcome in mRCC patients and thyroid hormone replacement does not have a negative effect on tumor outcome.
- Keywords : Hypothyroidism; metastatic renal cell carcinoma; overall survival; progression-free survival, sunitinib
- September 2024, 34 (3)
Full Text(PDF) Free- Social Network Service
-
- Services
- Cited By Articles
-
CrossRef (0)
